Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)

By sjmartinez • April 7, 2023

Kusuma FK, Prabhu A, Tieo G, Ahmed SM, Dakle P, Yong WK, Pathak E, Madan V, Jiang YY, Tam WL, Kappei D, Dröge P, Koeffler HP, Jeitany M. Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT). Nat Commun. 2023 Apr 6;14(1):1919. doi: 10.1038/s41467-023-37633-3. PMID: 37024489.

Tags: Cedars Sinai DoM, Hematology/Oncology, Publications

Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study

Wang R, Wang S, Mi Y, Huang T, Wang J, Ni J, Wang J, Yin J, Li M, Ran X, Fan S, Sun Q, Tan[...]

Observational study of sudden cardiac arrest risk (OSCAR): Rationale and design of an electronic health records cohort

Reinier K, Chugh HS, Uy-Evanado A, Heckard E, Mathias M, Bosson N, Calsavara VF, Slomka PJ, Elashoff DA, Bui AAT, Chugh SS. Observational study of[...]

Health System, Community-Based, or Usual Dementia Care for Persons With Dementia and Caregivers: The D-CARE Randomized Clinical Trial

Reuben DB, Gill TM, Stevens A, Williamson J, Volpi E, Lichtenstein M, Jennings LA, Galloway R, Summapund J, Araujo K, Bass D, Weitzman L, Tan[...]